From the blog

ERAS® Guidelines Validation of CRS With or Without HIPEC

Published: January 28, 2022

Primary Outcome Measures

  1. Compliance of ERAS® guidelines [ Time Frame: 3 months ]
    Post-ERAS® implementation phase: compliance rate towards the relevant core items from ERAS guidelines

Secondary Outcome Measures

  1. Acceptance and feasibility of ERAS® guidelines [ Time Frame: 3 months ]
    Pre-ERAS® phase (current clinical practice): current compliance rate towards the ERAS guidelines

Inclusion Criteria

  • Adults female and male patients (> 18 year-old)
  • Peritoneal cancer from colorectal, ovarian, gastric, appendix origin and primitive peritoneal cancer (peritoneal mesothelioma)
  • Multidisciplinary team meeting validation for CRS/HIPEC
  • Informed and signed surgical consent

Exclusion Criteria

  • Patients without peritoneal cancer
  • Patients with peritoneal cancer and extended extraperitoneal metastases contraindicating for CRS with or without HIPEC
  • No informed consent signed
Contact Us
CONTACT INFORMATION
DIAGNOSIS
Have you received a diagnosis? *
reCAPTCHA

Quick Facts

Added:
January 28, 2022

Last Updated:
January 28, 2022

Accepts Healthy Volunteers:


Ages Eligible for Study:
18 Years and older (Adult, Older Adult)

ClinicalTrials.gov Identifier:
NCT05185791

Contact:


Estimated Enrollment:
288

Estimated Primary Completion Date:
June 30, 2022

Estimated Study Start Date:
October 1, 2021

Genders Eligible for Study:
All

Status:
Recruiting